Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma

An elderly patient with multiple myeloma (MM) was being treated with several regimens and developed a severe drug eruption, necessitating the use of atovaquone instead of trimethoprim-sulfamethoxazole for pneumocystis pneumonia (PCP) prophylaxis. For progressive MM, treatment with isatuximab, an ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Toshiyuki, Ohta, Takanori, Imanaga, Hiroshi, Nakazawa, Megumi, Sato, Yoriko, Sugio, Yasuhiro, Uchida, Yujiro, Ohno, Yuju, Uehara, Yasufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666232/
https://www.ncbi.nlm.nih.gov/pubmed/34024861
http://dx.doi.org/10.2169/internalmedicine.7509-21
Descripción
Sumario:An elderly patient with multiple myeloma (MM) was being treated with several regimens and developed a severe drug eruption, necessitating the use of atovaquone instead of trimethoprim-sulfamethoxazole for pneumocystis pneumonia (PCP) prophylaxis. For progressive MM, treatment with isatuximab, an anti-CD38 monoclonal antibody, was started. During the treatment, he developed Listeria monocytogenes bacteremia and recovered quickly with ampicillin administration. CD38 is closely related to the innate immune response against L. monocytogenes, and isatuximab may increase the risk of infection. Therefore, trimethoprim-sulfamethoxazole may be useful in the prevention of not only PCP but also L. monocytogenes infection.

Ejemplares similares